Stocks Market
Promopharm Q1 2026 Revenue Slides 1.9% to DH208.2m Amid Hospital Sales Dip
Promopharm’s first‑quarter 2026 turnover fell to DH208.2 million, a 1.9 % dip from the same period last year, primarily driven by weaker hospital‑segment sales. Despite the slight decline, the firm kept commercial momentum alive with successful new‑product launches, trimmed its total debt to DH182 million, and invested DH1.49 million in expanding production capacity. The modest revenue contraction is set against a stable overall market and disciplined financial management, suggesting limited immediate impact on the Moroccan pharmaceutical landscape.
Listen to this article
Unlock audio versions of premium articles and more with a Pro subscription.
Financial Highlights
Promopharm reported a Q1 2026 turnover of DH208.2 million, down 1.9 % from DH212.2 million a year earlier.
Sales Mix
The decline is mainly linked to slower sales in the hospital segment, while the broader market remained stable. New product launches, however, helped sustain commercial momentum throughout the quarter.
Debt Position
Financial debt stood at DH182 million as of 31 March 2026, compared with DH192 million at the end of 2025. The reduction reflects regular debt‑service payments and a disciplined approach to financial management.
Capital Expenditure
Investments during the quarter amounted to DH1.49 million, primarily directed toward expanding production capacity to support future growth drivers and to optimise the industrial footprint.
Overall, the modest revenue contraction is offset by debt reduction and strategic spending, indicating a neutral short‑term outlook for the company.